실시간 주요 뉴스 PUSH 알림서비스를 구독할 수 있습니다.
Samsung Biologics CEO John Rim pledged to expand the company’s core contract manufacturing business as it undergoes a major corporate restructuring with the planned spin-off of its biosimilar unit while maintaining its CDMO momentum.